HomeCompareTHAR vs PEP

THAR vs PEP: Dividend Comparison 2026

THAR yields 57.64% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 THAR wins by $437.9K in total portfolio value
10 years
THAR
THAR
● Live price
57.64%
Share price
$3.47
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$579.9K
Annual income
$131,396.64
Full THAR calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — THAR vs PEP

📍 THAR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHARPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THAR + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
THAR pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THAR
Annual income on $10K today (after 15% tax)
$4,899.14/yr
After 10yr DRIP, annual income (after tax)
$111,687.14/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, THAR beats the other by $59,092.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THAR + PEP for your $10,000?

THAR: 50%PEP: 50%
100% PEP50/50100% THAR
Portfolio after 10yr
$360.9K
Annual income
$96,636.16/yr
Blended yield
26.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

THAR
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
0.4
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THAR buys
0
PEP buys
0
No recent congressional trades found for THAR or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHARPEP
Forward yield57.64%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$579.9K$141.9K
Annual income after 10y$131,396.64$61,875.67
Total dividends collected$477.1K$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: THAR vs PEP ($10,000, DRIP)

YearTHAR PortfolioTHAR Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$16,464$5,763.69$10,849$509.42+$5.6KTHAR
2$26,485$8,868.37$11,969$750.47+$14.5KTHAR
3$41,671$13,332.91$13,500$1,124.14+$28.2KTHAR
4$64,194$19,605.90$15,680$1,721.66+$48.5KTHAR
5$96,915$28,226.79$18,929$2,715.34+$78.0KTHAR
6$143,525$39,826.39$24,023$4,450.80+$119.5KTHAR
7$208,694$55,122.07$32,510$7,669.92+$176.2KTHAR
8$298,210$74,907.23$47,709$14,093.60+$250.5KTHAR
9$419,119$100,035.01$77,415$28,083.48+$341.7KTHAR
10$579,854$131,396.64$141,922$61,875.67+$437.9KTHAR

THAR vs PEP: Complete Analysis 2026

THARStock

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Full THAR Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this THAR vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THAR vs SCHDTHAR vs JEPITHAR vs OTHAR vs KOTHAR vs MAINTHAR vs MOTHAR vs PMTHAR vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.